<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940393</url>
  </required_header>
  <id_info>
    <org_study_id>GACE-01</org_study_id>
    <nct_id>NCT01940393</nct_id>
  </id_info>
  <brief_title>Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria</brief_title>
  <official_title>Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Alergología Clínica y Experimental</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Alergología Clínica y Experimental</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antihistamines with inhaled steroids are the cornerstone on the symptomatic therapy in
      the management of patients with rhinitis and the first line of treatment in patients with
      urticaria. Currently, the use of antihistamines has become popular due to its excellent
      safety profile and clinical efficacy, however to the investigators knowledge, there are no
      studies about the pharmacokinetic and pharmacodynamic effects of these drugs in patients of
      tropical Latin America. The investigators main interest is to evaluate if skin test
      inhibition correlates with the clinical effect of five anti-histamines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, study that was conducted in six health care centers from
      Medellín and Bogotá (Colombia). This study was conducted in compliance with the ethical
      principles of the Declaration of Helsinki and with Good Clinical Practice guidelines. Written
      informed consent was obtained from all subjects or they parents in patients under 18 years.
      Ethical committee of University of Antioquia (Medellín, Colombia) approved the protocol.
      Considering the large number of articles that demonstrate the efficacy of antihistamines as
      first-line treatment in patients with urticaria, the ethics committee request that all
      participants would receive an antihistamine during the two months of the study because a
      placebo group would provide little information for the principal objective and the high risk
      of airway angioedema. Thirty heath subjects were used as a control group to evaluated the
      characteristics of the wheal in the prick test with histamine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with uticaria that improved Urticaria Activity Score and Life Quality Index (DLQI) with the use of antihistamine in mono-dose and quadruple dose.</measure>
    <time_frame>Patients will be followed for two months</time_frame>
    <description>Each patient will be assigned to receive the standard dose of one antihistamine for one month. The assignment of each patient group for each antihistamine will be using a double-blind system.
In the second month, patients who do not achieve good control, will receive a quadrupled dose of the same antihistamine received in the first month.
A medical evaluation, symptoms scales (UAS and DLQI) and prick test with histamine will be performed at enrollment and during the first and second months of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety issue</measure>
    <time_frame>2 months</time_frame>
    <description>Safety and tolerability were assessed by adverse events reported by subjects at each postrandomization clinic visit. We did electrocardiogram and laboratory examination before initiation of antihistamine therapy and each month after (complete blood count [CBC], aspartate aminotransferase [AST], alanine aminotransferase [ALT], creatinine, blood urea nitrogen). We did an specific questionnaire (in spanish) to assess sedation:
&quot;¿Sientes más sueño o somnolencia de lo acostumbrado?&quot; (Do you feel more sleepy or drowsy than usual?), &quot;¿Sientes que el sueño o la somnolencia interfiere con tus actividades diarias?&quot; (Do you feel sleep or sleepiness interferes with your daily activities?), &quot;¿Sientes que tú sueño no es reparador?&quot; (Do you feel that you sleep is not restful?). Each question could be answered from 0 to 3 points (0 no 1. little, 2 moderate, 3 much). the sum of points defined them the severity of sedation in mild (0-3), moderate (4-5) and severe sedation (6-9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholinergic and physical urticarias</measure>
    <time_frame>2 months</time_frame>
    <description>We asked to each patients about physical triggers and with physical provocation test, we evaluated in all patients if wheals are evoked by a cholinergic or physical stimulus such as water, pressure, friction or cold contact.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Urticaria</condition>
  <arm_group>
    <arm_group_label>Cetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetirizine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desloratadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fexofenadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ebastine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ebastine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilastine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bilastine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine</intervention_name>
    <description>Drug administration</description>
    <arm_group_label>Cetirizine</arm_group_label>
    <other_name>Alercet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine</intervention_name>
    <description>Drug Administration</description>
    <arm_group_label>Desloratadine</arm_group_label>
    <other_name>Aerius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>Drug administration</description>
    <arm_group_label>Fexofenadine</arm_group_label>
    <other_name>Allegra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ebastine</intervention_name>
    <description>Drug administration</description>
    <arm_group_label>Ebastine</arm_group_label>
    <other_name>Pinaval</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine</intervention_name>
    <description>Drug administration</description>
    <arm_group_label>Bilastine</arm_group_label>
    <other_name>Bilaxten</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of persistent allergic urticaria.

          -  Age over 12 years and at least one year with the disease

          -  Informed consent filled.

          -  Be resident of the metropolitan area of Medellin.

        Exclusion Criteria:

          -  • Use of immunosuppressive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Sánchez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>IPS Universitaria, University of Antioquia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medellin</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2013</study_first_submitted>
  <study_first_submitted_qc>September 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>February 16, 2014</last_update_submitted>
  <last_update_submitted_qc>February 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo de Alergología Clínica y Experimental</investigator_affiliation>
    <investigator_full_name>Jorge Sanchez</investigator_full_name>
    <investigator_title>M.D, M.Sc, Allergist</investigator_title>
  </responsible_party>
  <keyword>urticaria</keyword>
  <keyword>bilastine</keyword>
  <keyword>fexofenadine</keyword>
  <keyword>cetirizine</keyword>
  <keyword>ebastine</keyword>
  <keyword>desloratadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
    <mesh_term>Ebastine</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

